Keywords: Roche, Genentech, ImmunoGen, Kadcyla, Trastuzumab emtanssine, Breast cancer, USA, FDA

US FDA approves Roche's late-stage breast cancer drug Kadcyla

Article | 25 February 2013

Print This

The US Food and Drug Administration on Friday approved Kadcyla (ado-trastuzumab emtansine), a new therapy for patients with HER2-positive, ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in